BRCA Mutated Breast Cancer This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 747790
Download Presentation The PPT/PDF document "Novel Strategies in the Management of P..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Novel Strategies in the Management of Progressive BRCA-Mutated Breast CancerSlide2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide3
OverviewSlide4
BRCA1/2 Testing CriteriaSlide5
BRCA1/2 Testing Criteria (cont)Slide6
DNA Damage Repair MechanismsSlide7
Pathways to Synthetic LethalitySlide8
Phase 1 Trials in Patients With Germline BRCA-Mutated Breast CancerSlide9
Phase 1 Trials in Patients With Germline BRCA-Mutated Breast Cancer (cont)Slide10
Randomized Phase 2 Study of Gemcitabine/Carboplatin With and Without IniparibSlide11
Randomized Phase 2 Study of Gemcitabine/Carboplatin With and Without Iniparib (cont)Slide12
BROCADE 2 Study: DesignSlide13
BROCADE 2 Study: ResultsSlide14
BrighTNess Study: TNBC and Continuous DosingSlide15
BrighTNess Study: Results Slide16
BrighTNess Study: Conclusions Slide17
ABRAZO TrialTalazoparib Phase 2 in gBRCA+ MBCSlide18
ABRAZO Trial: Primary Efficacy Endpoint ORR by Independent Radiologist FacilitySlide19
EMBRACA Phase 3 StudySlide20
EMBRACA Phase 3 Study (cont)Slide21
OlympiAD Study DesignSlide22
OlympiAD Study: Primary Endpoint
PFS by BICRSlide23
OlympiAD Study: Time to Second Progression or Death (PFS2) by Investigator AssessmentSlide24
OlympiAD Study: AEsSlide25
OlympiAD: AEs (cont)Slide26
Clinical ImplicationsSlide27
Challenges and Unanswered QuestionsSlide28